Axsome sells fast-acting depression medicine Auvelity.
Axsome Therapeutics, Inc. (AXSM) is expected to report earnings on Monday, November 2, 2026, after the close. Estimated release time 07:08 ET. Consensus EPS estimate is $-0.54.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-10 | FY2026 Q2 | $-0.89 | $-0.99 | -11.0% | $218.38M |
| 2026-05-04 | FY2026 Q1 | $-0.85 | $-1.26 | -48.2% | $191.20M |
| 2026-02-23 | FY2025 Q4 | $-0.70 | $-0.56 | +20.0% | $196.00M |
| 2025-11-03 | FY2025 Q3 | $-0.82 | $-0.94 | -14.6% | $170.99M |
| 2025-08-04 | FY2025 Q2 | $-1.00 | $-0.97 | +3.0% | $150.04M |
| 2025-05-05 | FY2025 Q1 | $-1.26 | $-1.22 | +3.2% | $121.46M |
| 2025-02-18 | FY2024 Q4 | $-1.00 | $-1.54 | -54.0% | $118.77M |
| 2024-11-12 | FY2024 Q3 | $-1.38 | $-1.34 | +2.9% | $104.76M |
AXSM has beaten consensus EPS in 4 of its last 8 reported quarters.
AXSM reported Aug 10. The highlights: EPS of -$0.99 — a miss vs the -$0.89 estimate (-11%); revenue of $218M — in line with the $221M consensus. Focus now shifts to Auvelity growth and pipeline.
See AXSM on the live calendar →